Lexeo Therapeutics, Inc. Common Stock (LXEO) Market Cap
Lexeo Therapeutics, Inc. Common Stock has a market capitalization of $445.3M.
Financials based on reported quarter end 2025-12-31
Price: $6.01
▼ -0.32 (-5.06%)
Market Cap: 445.26M
NASDAQ · time unavailable
CEO: R. Nolan Townsend
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2023-11-03
Website: https://www.lexeotx.com
Lexeo Therapeutics, Inc. Common Stock (LXEO) - Company Information
Market Cap: 445.26M · Sector: Healthcare
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Analyst Sentiment
Based on 5 ratings
Analyst 1Y Forecast: $18.78
Average target (based on 2 sources)
Consensus Price Target
Low
$10
Median
$20
High
$25
Average
$19
Potential Upside: 207.8%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"LXEO reported net income of -$20.9M for the most recent quarter ended 2025-12-31 (EPS reported as +$0.06, which is directionally inconsistent with the negative net income figure provided). Revenue is shown as $0 in the dataset, so near-term top-line traction cannot be assessed from these inputs. Free cash flow (FCF) was -$20.1M, driven by operating cash flow of -$20.1M, with $0 capex and no dividends paid. Balance sheet resilience appears moderate: total assets were $268.7M versus total liabilities of $22.0M, leaving equity of $246.7M. Net debt was -$55.1M, indicating net cash (more cash than debt based on this metric). On valuation and market performance, the stock price was $5.74 and up 65.4% over 1 year, though down 13.6% over 6 months and 40.3% year-to-date—suggesting recent sentiment volatility. With limited fundamentals visibility (notably revenue and FCF yield/P-E metrics are missing), the creditable picture is: strong balance sheet net cash position, but currently negative operating cash flow and no shareholder payouts. Analyst target consensus is $20.14 (range $10–$30), reflecting substantial upside implied by sell-side expectations, though this summary does not treat it as a recommendation."
Revenue Growth
Revenue is provided as $0 for the quarter, so growth/stability cannot be evaluated from the supplied dataset.
Profitability
Net income was -$20.9M, indicating losses. EPS is shown as +$0.06, which conflicts with net income and limits confidence in profitability assessment.
Cash Flow Quality
Operating cash flow was -$20.1M and FCF was -$20.1M, with no dividends and no buyback data provided—cash generation remains a key weakness.
Leverage & Balance Sheet
Total liabilities were $22.0M against $246.7M equity. Net debt was -$55.1M (net cash), improving financial resilience.
Shareholder Returns
Total shareholder return is mixed: no dividends were paid and no buybacks were provided, but the shares are up 65.4% over 1 year, partially offsetting weak fundamentals.
Analyst Sentiment & Valuation
Analyst consensus target is $20.14 versus a $5.74 price, implying bullish expectations. However, valuation multiples (P/E, FCF yield, ROE, debt/equity) are missing from the dataset.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.